Key Insights

Highlights

Success Rate

98% trial completion (above average)

Published Results

55 trials with published results (29%)

Research Maturity

161 completed trials (85% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

2.1%

4 terminated out of 189 trials

Success Rate

97.6%

+11.1% vs benchmark

Late-Stage Pipeline

63%

120 trials in Phase 3/4

Results Transparency

34%

55 of 161 completed with results

Key Signals

55 with results98% success

Data Visualizations

Phase Distribution

178Total
Not Applicable (10)
P 1 (16)
P 2 (32)
P 3 (75)
P 4 (45)

Trial Status

Completed161
Unknown10
Recruiting8
Terminated4
Withdrawn3
Not Yet Recruiting2

Trial Success Rate

97.6%

Benchmark: 86.5%

Based on 161 completed trials

Clinical Trials (189)

Showing 20 of 20 trials
NCT07457060Phase 4RecruitingPrimary

Phase IV Clinical Study of Sequential Vaccination of Sabin Strain and Wild Strain Inactivated Poliovirus Vaccine

NCT07073144Not ApplicableCompleted

The Impact of 'Digital Strolling' on Depression and Quality of Life of People With Severe Mobility Impairment

NCT07354269Phase 4RecruitingPrimary

Phase IV Clinical Study of sIPV Administration in Adolescent and Adult Populations

NCT06442449Phase 4CompletedPrimary

Booster Dose of sIPV Co-administered With MMR and HepA-I.

NCT06895486Phase 2RecruitingPrimary

Study of Co-administered (Types 1 & 2) Novel Oral Poliomyelitis Vaccines Evaluation

NCT05644184Phase 2RecruitingPrimary

Study of a Novel Type 1 Oral Poliomyelitis Vaccine in Bangladesh

NCT03891758Phase 3Completed

Confirmatory Study of BK1310 in Healthy Infants

NCT07297186Phase 3CompletedPrimary

Phase III Clinical Trial of Sabin Strain Inactivated Poliovirus Vaccine (Vero Cell)

NCT05850364Phase 3CompletedPrimary

A Multi-center, Open-labelled, Randomized, Controlled, Extended Phase Ⅲ Clinical Trial of sIPV Vaccine

NCT05951985Not ApplicableCompleted

High Intensity Functional Training for Individuals With Neurologic Diagnoses and Their Care Partners

NCT07010822Phase 3Not Yet RecruitingPrimary

A Study to Evaluate the Mucosal Intestinal Immunity to Poliovirus Type-2 of nOPV2 at Birth Dose in Healthy IPV Vaccinated Infants

NCT06577298Phase 1RecruitingPrimary

A Study to Evaluate the Safety and Immunogenicity of VLP-Polio in Infants and Toddlers

NCT06947499Phase 2Recruiting

A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series

NCT06137664Phase 1RecruitingPrimary

Study of Trivalent and Bivalent (Types 1 & 2) Novel Oral Poliomyelitis Vaccines

NCT02089880Not ApplicableActive Not Recruiting

Comparing Functional Outcomes in Individuals Using Micro-processor Controlled Orthosis Versus Stance Control Orthosis

NCT05431933Phase 3CompletedPrimary

Study to Evaluate Eupolio(IPV)'s Safety, Long-term Protective Effect and Boosting Effect of One Booster Dose in the Three Primary Vaccination Plus Boosting Schedule, and Protective Effect in the Schedule With Bivalent OPV in Infants

NCT05460377Phase 4CompletedPrimary

Assessing Immunogenicity of Intramuscular Sabin Inactivated Poliovirus Vaccine and Non-inferiority of Intradermal Fractional Inactivated Poliovirus Vaccine

NCT06346834Phase 4CompletedPrimary

Sequential Vaccination of Poliomyelitis Vaccine (Vero Cells), Inactivated, Sabin Strains From Different Manufacturers

NCT06752174Phase 3CompletedPrimary

A Study to Evaluate Safety and Immunogenicity of Sequential Vaccination of Sabin Inactivated Poliomyelitis Vaccine (Vero Cell) and Live Attenuated Poliomyelitis Vaccine in Healthy 2-month-old Infants

NCT06101173Phase 1CompletedPrimary

A Study to Evaluate the Safety and Immunogenicity of Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) in Healthy Adults

Scroll to load more

Research Network

Activity Timeline